Categories AlphaGraphs, Earnings, Health Care
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided by an increase in revenues.
First-quarter worldwide sales increased 9% year-over-year to $15.8 billion, mainly reflecting sustained growth across the oncology and vaccine portfolios.
The company reported a net profit of $4.76 billion or $1.87 per share for the March quarter, compared to $2.82 billion or $1.11 per share in the prior-year period. On an adjusted basis, earnings climbed to $2.07 per share in Q1 from $1.40 per share in the first quarter of 2023.
“Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients,” said Merck’s CEO Robert Davis.
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Netflix (NFLX) stands tall in a heavily competitive streaming landscape
Shares of Netflix, Inc. (NASDAQ: NFLX) were down over 2% on Friday. The stock has gained 27% over the past three months. The streaming giant continues to hold its ground
Starbucks (SBUX): A look at the challenges that continue to beleaguer the coffee giant
Shares of Starbucks Corporation (NASDAQ: SBUX) rose 2% on Thursday. The stock has dropped 9% over the past month. The company has faced its fair share of challenges during fiscal
Broadcom (AVGO) thrives on growing AI business. Is the stock a buy?
Broadcom, Inc. (NASDAQ: AVGO), a leading provider of semiconductor solutions for wired and wireless communications, recently impressed the market with upbeat financial outlook highlighting strong prospects for its AI business
